| 第二代环氧酶-2特异性抑制剂的研究进展 |
| |
| 引用本文： | 安富荣,曹惠明. 第二代环氧酶-2特异性抑制剂的研究进展[J]. 药学服务与研究, 2004, 4(2): 173-177 |
| |
| 作者姓名： | 安富荣 曹惠明 |
| |
| 作者单位： | 上海第二医科大学附属仁济医院药剂科,上海,200001 |
| |
| 摘 要： | 为降低NSAIDs类药物的典型胃肠道不良反应，人们开发了选择性更高的第二代环氧酶-2(COX-2)特异性抑制剂。已开发的代表性化合物有戊地昔布、帕瑞昔布、依地昔布和氯美昔布等。临床试验证实，这些药物具有可靠的抗炎和止痛作用，其中帕瑞昔布作为第一个注射用NSAIDs类药物，可用于治疗手术后疼痛。本文综述该领域的研究进展。
|
| 关 键 词： | 环氧酶-2抑制剂 戊地昔布 帕瑞昔布 依地昔布 氯美昔布 综述 |
| 文章编号： | 1671-2838(2004)02-0173-05 |
| 修稿时间： | 2003-09-03 |
The second generation of cyclooxygenase-2 specific inhibitors |
| |
| AN Fu-Rong,CAO Hui-Ming. The second generation of cyclooxygenase-2 specific inhibitors[J]. Pharmaceutical Care and Research, 2004, 4(2): 173-177 |
| |
| Authors: | AN Fu-Rong CAO Hui-Ming |
| |
| Abstract: | The second generation of COX-2 specific inhibitors with high cyclooxygenase-2(COX-2) selectivity was developed with the promise of further reduction of NSAID-typical adverse effects. The leading compounds are valdecoxib, parecoxib, etoricoxib and lumiracoxib. They have been proven to have efficacy in the treatment of pain and inflammation. Parecoxib as the first parenteral drug of NSAIDs has the potential to become the drug of choice for treatment of postoperative pain. In this article, the experiences of clinical use of valdecoxib, parecoxib, etoricoxib and lumiracoxib are reviewed. |
| |
| Keywords: | COX-2 inhibitor valdecoxib parecoxib etoricoxib lumiracoxib review |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
